Loading clinical trials...
Loading clinical trials...
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study
Conditions
Interventions
GSK580299 (Cervarix)
Locations
28
United States
GSK Investigational Site
Aurora, Colorado, United States
GSK Investigational Site
Golden, Colorado, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Augusta, Georgia, United States
GSK Investigational Site
Iowa City, Iowa, United States
Start Date
April 1, 2011
Primary Completion Date
November 23, 2017
Completion Date
November 23, 2017
Last Updated
June 19, 2019
NCT01627561
NCT00637195
NCT00196937
NCT01462357
NCT00534638
NCT01190176
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions